JSKN003
Drug timelines are a Plus or Pro feature.
7 regulatory and trial events tracked for JSKN003, covering 2024-12-31 to 2026-04-22. Get the full timeline:
Most recent: Clinical Trial Update: A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer [Phase 2]